FDA PMA
FDA Class 3
Approved
🇺🇸 United States
Hybrid Stent Graft, Thoracic Aortic Lesion Treatment
PMA: P210006
·
Supplement: S016
·
Decision Jan 29, 2026
Classifications
1
FEI Numbers
0
Registration Numbers
0
Basic Information
- Device Name
- Hybrid Stent Graft, Thoracic Aortic Lesion Treatment
- Trade Name
- Thoraflex Hybrid
- PMA Number
- P210006
- Supplement Number
- S016
- Device Class
- FDA Class 3
- Product Code
- QSK
- Generic Name
- Hybrid stent graft, thoracic aortic lesion treatment
- Medical Specialty
- Unknown
- Advisory Committee
- Cardiovascular
- Decision
- Approved
- Decision Code
- APPR
- Decision Date
- January 29, 2026
- Date Received
- December 30, 2025
- Supplement Type
- Special (Immediate Track)
- Supplement Reason
- Labeling Change - Indications/instructions/shelf life/tradename
- Expedited Review
- N
Advisory Committee Statement
an update to the lFU to include additional language regarding early imaging surveillance for patients at risk for intraluminal thrombosis
Classifications
This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.
| Product Code | Device Name | Device Class | Medical Specialty |
|---|---|---|---|
| QSK | Hybrid Stent Graft, Thoracic Aortic Lesion Treatment | FDA class 3 | Unknown |